Cargando…
Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612121/ https://www.ncbi.nlm.nih.gov/pubmed/36298593 http://dx.doi.org/10.3390/vaccines10101728 |
_version_ | 1784819700466712576 |
---|---|
author | Błaszczuk, Agata Michalski, Aleksander Sikora, Dominika Malm, Maria Drop, Bartłomiej Polz-Dacewicz, Małgorzata |
author_facet | Błaszczuk, Agata Michalski, Aleksander Sikora, Dominika Malm, Maria Drop, Bartłomiej Polz-Dacewicz, Małgorzata |
author_sort | Błaszczuk, Agata |
collection | PubMed |
description | The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies. |
format | Online Article Text |
id | pubmed-9612121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96121212022-10-28 Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant Błaszczuk, Agata Michalski, Aleksander Sikora, Dominika Malm, Maria Drop, Bartłomiej Polz-Dacewicz, Małgorzata Vaccines (Basel) Article The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies. MDPI 2022-10-16 /pmc/articles/PMC9612121/ /pubmed/36298593 http://dx.doi.org/10.3390/vaccines10101728 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Błaszczuk, Agata Michalski, Aleksander Sikora, Dominika Malm, Maria Drop, Bartłomiej Polz-Dacewicz, Małgorzata Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title_full | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title_fullStr | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title_full_unstemmed | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title_short | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
title_sort | antibody response after sars-cov-2 infection with the delta and omicron variant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612121/ https://www.ncbi.nlm.nih.gov/pubmed/36298593 http://dx.doi.org/10.3390/vaccines10101728 |
work_keys_str_mv | AT błaszczukagata antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT michalskialeksander antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT sikoradominika antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT malmmaria antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT dropbartłomiej antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT polzdacewiczmałgorzata antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant |